IDH1 and glioma: Preclinical breakthroughs have paved the way for the development of a myriad of IDH-targeted therapies, including small molecule IDH inhibitors (directed against IDH1 and IDH2 mutations) and vaccines that elicit immunogenic responses against glioma cells with these mutations.